Product Name
AGPAT2, Blocking Peptide
Full Product Name
AGPAT2 Peptide
Product Gene Name
AGPAT2 blocking peptide
[Similar Products]
Product Synonym Gene Name
1-AGPAT2; BSCL; BSCL1; LPAAB; LPAAT-beta[Similar Products]
AGPAT2 peptide (MBS3232430) is used for blocking the activity of AGPAT2 antibody (MBS3207465)
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for Q5VUD3
Form/Format
Lyophilized powder
Preparation and Storage
Add 100ul of sterile PBS. Final peptide concentration is 1 mg/ml in PBS. For longer periods of storage, store at -20 degree C. Avoid repeat freeze-thaw cycles.
Other Notes
Small volumes of AGPAT2 blocking peptide vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
AGPAT2 blocking peptide
This is a synthetic peptide designed for use in combination with anti-AGPAT2 antibody made
Target Description: AGPAT2 is a member of the 1-acylglycerol-3-phosphate O-acyltransferase family. The protein is located within the endoplasmic reticulum membrane and converts lysophosphatidic acid to phosphatidic acid, the second step in de novo phospholipid biosynthesis. Mutations in its gene have been associated with congenital generalized lipodystrophy (CGL), or Berardinelli-Seip syndrome, a disease characterized by a near absence of adipose tissue and severe insulin resistance.This gene encodes a member of the 1-acylglycerol-3-phosphate O-acyltransferase family. The protein is located within the endoplasmic reticulum membrane and converts lysophosphatidic acid to phosphatidic acid, the second step in de novo phospholipid biosynthesis. Mutations in this gene have been associated with congenital generalized lipodystrophy (CGL), or Berardinelli-Seip syndrome, a disease characterized by a near absence of adipose tissue and severe insulin resistance. Alternate transcriptional splice variants, encoding different isoforms, have been characterized.
Product Categories/Family for AGPAT2 blocking peptide
Peptide
Applications Tested/Suitable for AGPAT2 blocking peptide
Western Blot (WB)
NCBI/Uniprot data below describe general gene information for AGPAT2. It may not necessarily be applicable to this product.
NCBI Accession #
NP_001012745
[Other Products]
NCBI GenBank Nucleotide #
NM_001012727
[Other Products]
UniProt Primary Accession #
Q5VUD3
[Other Products]
UniProt Related Accession #
O15120[Other Products]
NCBI Official Full Name
1-acyl-sn-glycerol-3-phosphate acyltransferase beta isoform b
NCBI Official Synonym Full Names
1-acylglycerol-3-phosphate O-acyltransferase 2
NCBI Official Symbol
AGPAT2??[Similar Products]
NCBI Official Synonym Symbols
BSCL; BSCL1; LPAAB; 1-AGPAT2; LPAAT-beta
??[Similar Products]
NCBI Protein Information
1-acyl-sn-glycerol-3-phosphate acyltransferase beta
Protein Family
1-acyl-sn-glycerol-3-phosphate acyltransferase
NCBI Summary for AGPAT2
This gene encodes a member of the 1-acylglycerol-3-phosphate O-acyltransferase family. The protein is located within the endoplasmic reticulum membrane and converts lysophosphatidic acid to phosphatidic acid, the second step in de novo phospholipid biosynthesis. Mutations in this gene have been associated with congenital generalized lipodystrophy (CGL), or Berardinelli-Seip syndrome, a disease characterized by a near absence of adipose tissue and severe insulin resistance. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. [provided by RefSeq, Jul 2008]
Research Articles on AGPAT2
1. The findings demonstrate that AGPAT2, which is mutated in patients with congenital generalized lipodystrophy and over-expressed in different types of cancer, is a direct transcriptional target of HIF-1, suggesting that upregulation of lipid storage by HIF-1 plays an important role in adaptation and survival of cancer cells under low oxygen conditions.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
